Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
15:30
16:00
1-2-1 Meetings / Networking Break
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
14:50
15:20
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr
...
Bi/Multispecifics
11:20
12:20
How can early-stage structural data ensure bispecific antibodies maintain simultaneous target engage
...
Lead Identification & Optimization
Lead Identification & Optimization
11:20
12:20
Optimizing protein therapeutics for clinical success: How can incorporating developability assessmen
...
Target Selection & Mechanisms of Action
Target Selection & Mechanisms of Action
09:05
10:05
What engineering strategies are used to enhance membrane antigen presentation, and why are they impo
...
Target Selection & Mechanisms of Action
Target Selection & Mechanisms of Action
16:00
16:30
As the world leader in antibody services, our decades of research experience converge with advanced
...
Formats & Scaffolds
16:00
16:30
Artificial intelligence (AI) is transforming antibody discovery and engineering. Ailux's platform sy
...
Bi/Multispecifics
16:00
16:30
Efficient bispecific antibody (bsAb) production requires precise assembly of multiple chains. Combin
...
Lead Identification & Optimization
Lead Identification & Optimization
16:00
16:30
The PioneerTM Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic lead generatio
...
Formats & Scaffolds
09:05
10:05
How to solve the challenges of small therapeutic windows for cytokine treatment Manufacturing and st
...
Bi/Multispecifics
16:30
17:30
How do translational efficacy and safety assessments contribute to the selection of optimal molecule
...
Lead Identification & Optimization
Lead Identification & Optimization
09:05
10:05
Are current antibody discovery platforms and screening strategies meeting our expectations for effec
...
Target Selection & Mechanisms of Action
Target Selection & Mechanisms of Action
11:20
12:20
What characteristics make a protein a “clean” target in terms of avoiding the off-target effects of
...
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
13:20
13:50
Aureka Biotechnologies is a pioneer in the next generation of antibody discovery and engineering via our three fundamental technologies. Our platforms integrate AI with high-throughput biology for a fast, closed-loop, integrative discovery process. AuraQuest accelerates antibody design via a unique synthetic biology design, while AuraGlow, an ultra-high-throughput screening system, evaluates functional performance. AuraPicasso, our generative AI engine, continuously refines antibody candidates using feedback from AuraQuest and AuraGlow. This closed-loop system enables fast iteration, ensuring the development of best-in-class therapeutics with enhanced efficacy and specificity. To date, we have delivered on challenges such as pH sensitive binders, dual-affinity molecules, and AI-first therapeutics.
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
17:30
18:30
Drinks-Canape Reception
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
15:20
15:30
Afternoon Refreshments
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
13:50
14:20
1-2-1 Meetings / Networking Break
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
14:20
14:50
1-2-1 Meetings / Networking Break
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
12:20
13:20
Networking Lunch
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
11:10
11:20
Morning Refreshments
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
10:40
11:10
1-2-1 Meetings / Networking Break
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
10:10
10:40
1-2-1 Meetings / Networking Break
Bi/Multispecifics
09:05
10:05
How do the structural formats of bispecific antibodies impact their stability, expression levels, an
...
Lead Identification & Optimization
Lead Identification & Optimization
16:30
17:30
Where does AI stand on de novo antibody design? How can human BCR and single cell sequencing data i
...
Target Selection and Mechanisms of Action
Target Selection & Mechanisms of Action
16:30
17:30
What are some challenges in affinity maturation of antibodies against membrane proteins and how have
...
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
08:30
09:00
Off-target binding is a significant hurdle in the development of antibody-based therapies, contribut
...
Bi/Multispecifics
Formats & Scaffolds
Target Selection & Mechanisms of Action
Lead Identification & Optimization
08:00
08:30
Registration
)
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr ...
)
)
Aureka Biotechnologies is a pioneer in the next generation of antibody discovery and engineering via our three fundamental technologies. Our platforms integrate AI with high-throughput biology for a fast, closed-loop, integrative discovery process. AuraQuest accelerates antibody design via a unique synthetic biology design, while AuraGlow, an ultra-high-throughput screening system, evaluates functional performance. AuraPicasso, our generative AI engine, continuously refines antibody candidates using feedback from AuraQuest and AuraGlow. This closed-loop system enables fast iteration, ensuring the development of best-in-class therapeutics with enhanced efficacy and specificity. To date, we have delivered on challenges such as pH sensitive binders, dual-affinity molecules, and AI-first therapeutics.)
Off-target binding is a significant hurdle in the development of antibody-based therapies, contribut ...
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)